Edition:
United States

Sorrento Therapeutics Inc (SRNE.OQ)

SRNE.OQ on NASDAQ Stock Exchange Capital Market

2.00USD
26 Apr 2017
Change (% chg)

-- (--)
Prev Close
$2.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
97,939
52-wk High
$8.35
52-wk Low
$1.55

Latest Key Developments (Source: Significant Developments)

Sorrento announces proposed public offering of common stock
Wednesday, 12 Apr 2017 04:12pm EDT 

Sorrento Therapeutics Inc :Sorrento announces proposed public offering of common stock.  Full Article

Sorrento therapeutics anti-CEA car-T demonstrates promising clinical activity and safety in phase IB clinical trial
Monday, 3 Apr 2017 01:25pm EDT 

Sorrento Therapeutics Inc : Sorrento therapeutics anti-cea car-t demonstrates promising clinical activity and safety in phase IB clinical trial . In addition, from a safety standpoint, HITM-SIR protocol was well tolerated . There were no grade 4 or grade 5 events related to anti-cea car-t, sirt, or combination . All colitis episodes resolved with il-2 dose reductions .Sorrento - "anti-cea car-t hai may represent a safe & well tolerated component of novel multi-modality regimens capable of meaningful disease control.".  Full Article

Sorrento Therapeutics- co, units, Hercules enters into a fourth amendment to a loan and security agreement
Friday, 24 Mar 2017 06:11am EDT 

Sorrento Therapeutics Inc : Sorrento Therapeutics- on March 23, 2017, co, units, Hercules entered into a fourth amendment to that certain loan and security agreement . Sorrento Therapeutics Inc - loan agreement provides for a term loan of up to $75.0 million, subject to funding in multiple tranches . Sorrento Therapeutics Inc - under amendment, hercules reduced minimum amount of unrestricted cash that company must maintain under loan agreement . Sorrento Therapeutics-as per amendment, co to repay to hercules, without repayment penalty, $20.0 million of outstanding principal, unpaid interest accrued thereon . Sorrento Therapeutics Inc - under amendment, parties agreed to change date by which company must achieve a fundraising milestone .Sorrento Therapeutics Inc - in accordance with amendment, on March 23, 2017, company repaid repayment amount.  Full Article

Sorrento, Wildcat announce resolution
Monday, 20 Mar 2017 08:00am EDT 

Sorrento Therapeutics Inc : Sorrento and Wildcat announce resolution . Sorrento Therapeutics - reached mutual resolution with wildcat capital with respect to Wildcat's seeking of inspection of co's private placement . Sorrento Therapeutics - co and Wildcat have engaged in talks relating to steps needed to undertake in order to increase Sorrento's shareholder value . Sorrento Therapeutics Inc - as part of its core immuno-oncology business, sorrento is preparing to file an IND for at least one car-T phase I study .Sorrento Therapeutics Inc - Sorrento makes no admission of liability or wrongdoing in connection with Wildcat's inspection demand.  Full Article

Sorrento Therapeutics files for non-timely 10-K
Thursday, 16 Mar 2017 06:19am EDT 

Sorrento Therapeutics Inc : Sorrento Therapeutics Inc files for non-timely 10-K - SEC filing . Sorrento Therapeutics - as a result of acquisitions, other one-time items occurring late in Q4 2016, it is unable to file form 10-K within prescribed time period .Sorrento Therapeutics - will require additional time to ensure adequate disclosure of certain information required to be included in the form 10-K.  Full Article

Sorrento Therapeutics unit says key endpoints met in EU Pivotal Bioequivalence Clinical Study for ZTlido
Monday, 9 Jan 2017 09:00am EST 

Sorrento Therapeutics Inc - : Sorrento subsidiary, Scilex Pharmaceuticals, announces key endpoints met in the European Union Pivotal Bioequivalence Clinical Study for its lead product, ZTlido™ .Sorrento Therapeutics Inc- Marketing Authorization Application is expected to be filed in mid-2017 for ZTlido.  Full Article

Sorrento Therapeutics' study for ztlido meets primary endpoint
Monday, 5 Dec 2016 07:00am EST 

Sorrento Therapeutics Inc : Sorrento Therapeutics Inc - study for lead investigational product, ztlido has met a primary endpoint . Sorrento subsidiary, Scilex Pharmaceuticals announces key endpoints met in pivotal bioequivalence clinical study for its lead product, ztlido .Scilex Pharmaceuticals Inc - full data will be resubmitted to FDA as part of 505(B)(2) new drug application (NDA) in mid-2017.  Full Article

Sorrento Therapeutics files for resale of up to 1.2 mln shares of co's common stock by selling stockholders
Friday, 2 Dec 2016 05:38pm EST 

Sorrento Therapeutics Inc :Sorrento Therapeutics files for resale of up to 1.2 million shares of co's common stock by selling stockholders - SEC filing.  Full Article

Scintilla Pharma, a unit of Sorrento Therapeutics, to buy Semnur Pharma
Monday, 15 Aug 2016 06:34pm EDT 

Sorrento Therapeutics : Scintilla will pay semnur an initial payment of $60 million, consisting of $40 million in cash and $20 million in shares of sorrento . Scintilla pharmaceuticals,a subsidiary of sorrento therapeutics, inc., to acquire semnur pharmaceuticals .Additional cash consideration of up to $140 million may be paid by scintilla to semnur upon achievement of certain milestones.  Full Article

Scintilla to acquire Scilex Pharmaceuticals
Monday, 8 Aug 2016 09:00am EDT 

Scintilla Pharmaceuticals Inc: In consideration for deal, Scilex equity holders to receive up to $70 million in stock of Scintilla, after next equity financing of Scintilla . Has entered into a binding term sheet to acquire Scilex Pharmaceuticals, Inc .Acquisition is contingent upon completion of each parties' due diligence and other customary closing conditions.  Full Article

More From Around the Web

BRIEF-Sorrento announces proposed public offering of common stock

* Sorrento announces proposed public offering of common stock Source text for Eikon: Further company coverage: